Refractive Error and Biometry in Retinopathy of Prematurity

San Ni Chen

Status: Completed

Conditions: Retinopathy of Prematurity

Treatments: Drug: Bevacizumab; Drug: Ranibizumab

Study type: Observational

Funder types: Other

Identifiers

NCT03334513

171026

Details and patient eligibility

About

The investigators compared long-term refractive and biometric outcomes in children with retinopathy of prematurity who received two different anti-vascular endothelial growth factor agents.

Full description

Purpose:

To compare refractive and biometric outcomes in patients with type 1 retinopathy of prematurity (ROP) treated with intravitreal injection of Ranibizumab (IVR), versus bevacizumab (IVB), at a corrected age of 3 years.

Methods:

A retrospective case series compared cycloplegic refractive statuses and biometric statuses in patients who received either IVR or IVB for Type 1 ROP, from April 2011 to April 2014.

Comparison of refractive errors and biometric findings between the two groups was performmed and multivariate analysis of possible factors contributive to visual acuity was also performmed

Enrollment: 35 patients

Sex: All

Ages: 3 to 3 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• children with type 1 retinopathy of prematurity
• children received anti-vascular endothelial growth factors (bevacizumab or ranibizumab)

Exclusion criteria

• children withour retinopathy of prematurity
• children with retinopathy of prematurity received laser therapy

Trial design

35 participants in 1 patient group

ROP group

Description:

children with retinopathy of prematurity received either bevacizumab or ranibizumab

Treatment:

Drug: Ranibizumab

Drug: Bevacizumab